Prevention of Disease and Mortality in Vaccinated Dogs Following Experimental Challenge With Virulent Leptospira. R LaFleur, J Dant, T Wasmoen. Intervet / Schering Plough Animal Health, Elkhorn, NE. Canine Leptospirosis can vary from subclinical infection to illness that ranges from mild to severe, including death, depending on the susceptibility of the dog, virulence of the […]
In-depth information about feline vaccinations and veterinary best practices.
Prevention of Leptospiremia and Leptospiruria Following Vaccination With a DAPPv + 4-way Leptospira Combination Vaccine Rhonda L. LaFleur, Jennifer C. Dant, Anna L. Tubbs, Huchappa Jayappa, David Sutton, Ian Tarpey Background: Leptospirosis, characterized by high fever, anorexia, vomiting, abdominal pain, diarrhea, myalgia, polyuria/polydipsia, jaundice, epistaxis, hematuria, and/or reproductive failure, continues to cause considerable morbidity among infected […]
Clinical Relevance Forty-two seronegative cats received an initial vaccination at 8 weeks of age and a booster vaccination at 12 weeks. All cats were kept in strict isolation for 3 years after the second vaccination and then were challenged with feline calicivirus (FCV) or sequentially challenged with feline rhinotracheitis virus (FRV) followed by feline panleukopenia […]
Abstract The aim of the study was to determine the efficacy of an inactivated feline leukemia virus (FeLV) vac-cine (Versifel® FeLV, Zoetis.) compared to a recombinant FeLV vaccine (Purevax® FeLV, Merial Animal Health) in young cats, exposed under laboratory conditions to a highly virulent challenge model. The study was designed to be consistent with the general immunogenicity […]
Purpose The purpose of this study was to compare the efficacy of two commercially available feline leukemia vaccines, Nobivac® Feline 2-FeLV (inactivated whole virus vaccine) and PureVax® Recombinant FeLV (live canarypox virus-vectored vaccine) following challenge with virulent feline leukemia virus. Read More about this study here
Abstract A fraction of cats exposed to feline leukemia virus (FeLV) effectively contain virus and resist persistent antigenemia/viremia. Using real-time PCR (qPCR) to quantitate circulating viral DNA levels, previously we detected persistent FeLV DNA in blood cells of non-antigenemic cats considered to have resisted FeLV challenge. In addition, previously we used RNA qPCR to quantitate […]
The availability of feline leukaemia virus {FeLV) vaccines has added a new and important dimension to the control of this infectious agent. FeLV vaccination is a controversial issue, however, partly because of differences in the formulation between the current products, partly because of conflicting claims by vaccine manufacturers and partly because experimental trials have shown […]
Twenty young adult specific pathogen-free cats were randomly divided into two groups of 10 animals each. One group was vaccinated with two doses of feline leukemia virus vaccine according to the manufacturer’s recommendations. All 20 cats were challenge exposed oronasally (4 times over a I-week period), beginning 3 weeks after immunization, with a virulent subgroup […]
Purpose The purpose of this study was to compare the efficacy of two commercially available feline leukemia vaccines, Nobivac® Feline 2-FeLV (inactivated whole virus vaccine) and PureVax® Recombinant FeLV (live canarypox virus-vectored vaccine) following challenge with virulent feline leukemia virus. Read More about this study here